United Therapeutics pens $216M deal to buy SteadyMed, neutralizing pump-based threat to PAH franchise

United Therapeutics pens $216M deal to buy SteadyMed, neutralizing pump-based threat to PAH franchise

SteadyMed’s pump technology. (SteadyMed)

Source: https://www.fiercebiotech.com/medtech/united-therapeutics-pens-216m-deal-to-buy-steadymed-neutralizing-pump-based-threat-to-pah